The prognostic significance of thrombocytosis in ovarian cancer
More details
Hide details
The First Departament of Obstetrics and Gynecology Medical Centre of Postgraduate Education, Warsaw, Poland
Medical University of Warsaw, Poland
Ann Agric Environ Med 2015;22(4):731–735
Ovarian cancer makes up 25–30% of all cases of cancers of the female genital tract. It has the highest mortality rate of any condition in oncological gynaecology. Early diagnosis is associated with a favourable 5-year survival prognosis. Many solid tumours have been detected with concomitant thrombocytosis. The tumour cell-induced platelet aggregation is a result of a direct integration of tumour cells with blood platelets. The aim of the present paper is an evaluation of platelet count as a prognostic parameter for ovarian cancer. Between 2000 – 2005, 349 patients with ovarian tumour (aged 12 – 88-years-old) underwent primary surgical treatment at a clinic. Ninety-seven patients with ovarian carcinomas underwent chemotherapy in the Oncology Centre. The control group comprised 252 women diagnosed with a histopathological lesion of mild intensity, whereas the cancer group constituted 97 women with a histopathologically-diagnosed malignant neoplasm. Thrombocytopaenia was assumed with a platelet count below 150G/L and thrombocythaemia at 350G/L and higher. Thrombocytosis often coincides with ascites and the cytoreduction decreases platelet count. There is a positive correlation between platelet count and tumour grading. Thrombocytosis was more frequently found in high grade tumours. There is also a positive correlation between platelet count and tumour stage according the International Federation of Gynaecology and Obstetrics (FIGO). Thrombocytosis was more frequently found in stage III and IV cancers. Patients with co-occurring thrombocytosis were found to have shorter survival periods and shorter time free from disease. This seems to give grounds for measuring platelet count before the primary surgical intervention, and suggests that the platelet count should be included in the panel of prognostic factors for patients with ovarian tumours.
Aneta Słabuszewska-Jóźwiak   
The First Departament of Obstetrics and Gynecology Medical Centre of Postgraduate Education, Warsaw, Poland
1. Markowska J, Markowska A. Epidemiologia i etiopatogeneza raka. In: Markowska J (ed.). Ginekologia Onkologiczna. Wroclaw, Urban & Partner, 2006.p.805–6 (in Polish).
2. Wojtukiewicz MZ. Zakrzepy a nowotwory. In: Łopaciuk S (ed.). Zakrzepy i zatory. Warsaw, Wydawnictwo Lekarskie PZWL, Wyd. II, 2002.p.105–124 (in Polish).
3. Von Tempelhoff GF, Heilmann L, Hommel G, Schneider D, Niemann F, Zoller H. Hyperviscosity syndrome in patients with ovarian carcinoma. Cancer. 1998; 82: 1104–11.
4. Pinedo HM, Verheul HMW, D’ Amato RJ, Folkman J. Involvement of platelets in tumor angiogenesis? Lancet. 1998; 352: 1775–1777.
5. Lavie O, Comerco G, Daras V, Bolger BS, Lopes A, Monaghan JM. Thrombocytosis in women with vulvar carcinoma. Gynecol Oncol. 1999; 72: 82–6.
6. Hefler L, Mayerhofer K,Leibman B, Obermair A, Reinthaller A, Kaintz C, et al. Tumor anemia and thrombocytosis In patient with vulvar cancer. Tumor Biol. 2000; 21: 309–14.
7. Gucer F, Moser F, Tamussino K, Reich O, Haas J, Arikan G, et al. Thrombocytosis as a prognostic factor in endometrial carcinoma. Gynecol Oncol. 1998; 70: 210–214.
8. Honn KV, Tang DG, Chen YQ. Adhesion molecules and sitespecific metastates. Florance, Scientific Press, 1992.
9. Morgan MA, Iyengar TD, Napiorkowski BE, Rubin SC, Mikuta JJ. The clinical course of deep vein thrombosis in patients with gynecologic cancer. Gynecol Oncol. 2002; 84: 67–71.
10. Murchison JT, Wylie L, Stockton DL. Excess risk of cancer in patients with primary venous thromboembolism: a national, population–based cohort study. British J Cancer 2004; 91: 92–95.
11. Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer. 2005; 15(104): 2822–2829.
12. Sorensen, HT, Mellemkjaer L, Olesn JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000; 343:1846–1850.
13. Rodriguez AO, Wun T, Chew H. Venous thromboembolism in ovarian cancer. Gynecol Oncol. 2007; 105: 784–790.
14. Sud R, Khorana AA, Cancer–associated thrombosis: risk factors, candidate biomarkers and risk model. Thrombosis Research. 2009; 123, S18-S21.
15. Gungor T, Kanat-Pektas M,Sucak A, Mollamahmutoglu C. The role of thrombocytosis in prognostic evaluation of epithelial ovarian tumors. Arch Gynecol Obstet. 2009; 279: 53–56.
16. Menczer J, Schejter E, Geva D, Ginath S, Zakut H. Ovarian carcinoma associated thrombocytosis: correlation with prognostic factors and with survival. Eur J Gynaecol Oncol. 1998; 19: 82–84.
17. Zeimet AG, Marth C, Muller-Holzner E, Daxenbichler G, Depunt O. Significance of thrombocytosis in patients with epithelial ovarian cancer. Am J Obstet Gynecol. 1994; 170: 549–554.
18. Li AJ, Madden AC, Cass I, Leuchter RS, Lagasse LD, Karlan BY. The prognostic significance of thrombocytosis in epithelial ovarian carcinoma. Gynecol Oncol. 2004; 92(1): 211–214.
19. Lee M, Kim SW, Nam EJ, Yim GW, Kim S, Kim YT. The impact of pretreatment thrombocytosis and persistent thrombocytosis after adjuvant chemotherapy in patients with advanced epithelial ovarian cancer. Gynaecol Oncol. 2011; 122: 238–241.
20. Demers M, Ho-TinNoe B, Schatzberg D, Yang JJ, Wagner DD. Increased efficancy of breast cancer chemotherapy in thrombocytopenic mice. Cancer Res. 2011; 71(5): 1540–1509.
21. Bozkurt N, Yuce K, Basaran M, Kose F, Ayhan A. Correlation of platelet count with second look laparotomy results and disease progression in patients with advanced epithelial ovarian cancer. Obstet Ggynecol. 2004; 103: 82–85.